天津医药
天津醫藥
천진의약
TIANJIN MEDICAL JOURNAL
2014年
8期
827-829
,共3页
刘存发%张秀军%殷述刚%李俊海%黄梅%曹健鹏%戴兵%张楠%李津凯%王永磊
劉存髮%張秀軍%慇述剛%李俊海%黃梅%曹健鵬%戴兵%張楠%李津凱%王永磊
류존발%장수군%은술강%리준해%황매%조건붕%대병%장남%리진개%왕영뢰
股动脉闭塞%裸支架%Silverhawk斑块旋切%Viabahn覆膜支架
股動脈閉塞%裸支架%Silverhawk斑塊鏇切%Viabahn覆膜支架
고동맥폐새%라지가%Silverhawk반괴선절%Viabahn복막지가
femoral artery occlusion%stent%silverhawk atherectomy%viabahn stent
目的:探讨TASC(Ⅱ)D型股动脉闭塞的腔内治疗方法及效果。方法回顾性分析2012年1月-2013年5月采用腔内治疗TASC(Ⅱ)D型股浅动脉闭塞26例(26肢)患者的临床资料。其中采用球囊扩张内支架置入13例(裸支架组,共植入支架31枚)、Silverhawk斑块旋切6例(Silverhawk斑块旋切组)、Viabahn覆膜支架2例(Viabahn覆膜支架组)。腔内手术未成功通过病变者5例给予前列地尔等扩血管药物治疗。通过手术前后踝肱指数(ABI)、螺旋CT血管成像(CTA)、数字减影血管造影(DSA)及症状改善情况来评价疗效;并于术后6个月复查CTA。结果26例中成功开通目标动脉21例(技术成功率80.7%),造影证实血流通畅,残留狭窄小于30%,术后患肢缺血症状缓解。术后1周ABI高于术前(0.77±0.10 vs 0.43±0.15,t=7.948,P<0.05)。6个月一期通畅比例分别为裸支架组9/13,Silver-hawk斑块旋切组4/6,Viabahn覆膜支架2/2。结论腔内治疗TASC(Ⅱ)D型股动脉闭塞可提高近期通畅率,Viabahn覆膜支架是治疗的新手段。
目的:探討TASC(Ⅱ)D型股動脈閉塞的腔內治療方法及效果。方法迴顧性分析2012年1月-2013年5月採用腔內治療TASC(Ⅱ)D型股淺動脈閉塞26例(26肢)患者的臨床資料。其中採用毬囊擴張內支架置入13例(裸支架組,共植入支架31枚)、Silverhawk斑塊鏇切6例(Silverhawk斑塊鏇切組)、Viabahn覆膜支架2例(Viabahn覆膜支架組)。腔內手術未成功通過病變者5例給予前列地爾等擴血管藥物治療。通過手術前後踝肱指數(ABI)、螺鏇CT血管成像(CTA)、數字減影血管造影(DSA)及癥狀改善情況來評價療效;併于術後6箇月複查CTA。結果26例中成功開通目標動脈21例(技術成功率80.7%),造影證實血流通暢,殘留狹窄小于30%,術後患肢缺血癥狀緩解。術後1週ABI高于術前(0.77±0.10 vs 0.43±0.15,t=7.948,P<0.05)。6箇月一期通暢比例分彆為裸支架組9/13,Silver-hawk斑塊鏇切組4/6,Viabahn覆膜支架2/2。結論腔內治療TASC(Ⅱ)D型股動脈閉塞可提高近期通暢率,Viabahn覆膜支架是治療的新手段。
목적:탐토TASC(Ⅱ)D형고동맥폐새적강내치료방법급효과。방법회고성분석2012년1월-2013년5월채용강내치료TASC(Ⅱ)D형고천동맥폐새26례(26지)환자적림상자료。기중채용구낭확장내지가치입13례(라지가조,공식입지가31매)、Silverhawk반괴선절6례(Silverhawk반괴선절조)、Viabahn복막지가2례(Viabahn복막지가조)。강내수술미성공통과병변자5례급여전렬지이등확혈관약물치료。통과수술전후과굉지수(ABI)、라선CT혈관성상(CTA)、수자감영혈관조영(DSA)급증상개선정황래평개료효;병우술후6개월복사CTA。결과26례중성공개통목표동맥21례(기술성공솔80.7%),조영증실혈류통창,잔류협착소우30%,술후환지결혈증상완해。술후1주ABI고우술전(0.77±0.10 vs 0.43±0.15,t=7.948,P<0.05)。6개월일기통창비례분별위라지가조9/13,Silver-hawk반괴선절조4/6,Viabahn복막지가2/2。결론강내치료TASC(Ⅱ)D형고동맥폐새가제고근기통창솔,Viabahn복막지가시치료적신수단。
Objective To investigate methods and results of endovascular treatment in TASC (Ⅱ) D-type femoral artery occlusion. Methods From January 2012 to May 2013, 26 cases (26 branches) of superficial femoral artery occlusion with endovascular treatment of TASC (Ⅱ) D-type superficial femoral artery occlusion were retrospectively reviewed. The effi-cacy was evaluated through ABI, CTA, DSA and symptoms improved. Results 26 branches were treated with endovascular methods. Technical success rate was 80.7%(21/26), including 13 branche with stent implantation, 6 branches with Silver-hawk atherectomy and 2 branches with Viabahn stent implantation. All patients were followed up for a mean period of (10.3 ± 1.2)months, primary patency rates at 6 months were 69.2%in stent group, 66.7%in Silverhawk atherectomy group and 100%in Viabahn stent group. Conclusion Endovascular treatment of TASC (Ⅱ) D-type femoral artery occlusion can lead to satisfactory short term patency rates, and Viabahn stent is the latest treatment.